2015 is stacking up to have a Summer of Interferon-Free hepatitis C drug approvals! So far we’ve had the following approvals for provincial Pharmacare coverage (addition to provincial “formulary”):

On June 29th, Ontario covered AbbVie’s Holkira Pak™ for genotype 1, on July 24th, Quebec covered both Gilead’s Harvoni™ and AbbVie’s Holkira Pak™ for genotype 1. And on World Hepatitis Day, July 28th British Columbia, Saskatchewan, Manitoba, and Yukon started to cover AbbVie’s Holkira Pak™ for genotype 1!  On August 6th we heard that AbbVie’s Holkira Pak™ would be covered in Nova Scotia. 

And…today, August 20, we received great news that another upcoming drug,  daclatasvir (Daklinza™) from Bristol-Myers Squibb, which has potential to treat all genotypes including hard-to-treat genotype 3, has received a Notice of Compliance from Health Canada.  Read full press release:

http://www.newswire.ca/news-releases/health-canada-approves-daklinza-daclatasvir-for-the-treatment-of-chronic-hepatitis-c-infection-across-multiple-genotypes-including-genotype-3-522375441.html